BR112019005428A2 - agentes, usos e métodos de tratamento - Google Patents
agentes, usos e métodos de tratamentoInfo
- Publication number
- BR112019005428A2 BR112019005428A2 BR112019005428A BR112019005428A BR112019005428A2 BR 112019005428 A2 BR112019005428 A2 BR 112019005428A2 BR 112019005428 A BR112019005428 A BR 112019005428A BR 112019005428 A BR112019005428 A BR 112019005428A BR 112019005428 A2 BR112019005428 A2 BR 112019005428A2
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- treatment methods
- antibodies
- treatment
- sortiline
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 102000019204 Progranulins Human genes 0.000 abstract 1
- 108010012809 Progranulins Proteins 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção se relaciona com anticorpos monoclonais anti-sortilina que foram descobertos serem úteis na correção de um nível deficiente de progranulina (pgrn). em particular, estes anticorpos podem ser usados no tratamento de demência frontotemporal (ftd) e esclerose lateral amiotrófica (als) e outros transtornos neurodegenerativos tais como doença de alzheimer (ad).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700419 | 2017-07-20 | ||
PCT/EP2018/069460 WO2019016247A2 (en) | 2017-07-20 | 2018-07-18 | AGENTS, USES AND METHODS OF TREATMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019005428A2 true BR112019005428A2 (pt) | 2019-07-16 |
Family
ID=63113476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019005428A BR112019005428A2 (pt) | 2017-07-20 | 2018-07-18 | agentes, usos e métodos de tratamento |
Country Status (25)
Country | Link |
---|---|
US (2) | US10894833B2 (pt) |
EP (1) | EP3655438A2 (pt) |
JP (1) | JP2020527152A (pt) |
KR (1) | KR20200031610A (pt) |
CN (1) | CN110945029A (pt) |
AR (1) | AR112563A1 (pt) |
AU (1) | AU2018303175A1 (pt) |
BR (1) | BR112019005428A2 (pt) |
CA (1) | CA3069391A1 (pt) |
CL (1) | CL2020000070A1 (pt) |
CO (1) | CO2019014090A2 (pt) |
CR (1) | CR20200027A (pt) |
DO (1) | DOP2020000006A (pt) |
EA (1) | EA201992688A1 (pt) |
EC (1) | ECSP20002935A (pt) |
IL (1) | IL271728B2 (pt) |
JO (1) | JOP20200007A1 (pt) |
MA (1) | MA49633A (pt) |
NI (1) | NI202000005A (pt) |
PE (1) | PE20210467A1 (pt) |
PH (1) | PH12019502869A1 (pt) |
RU (1) | RU2019140933A (pt) |
SG (1) | SG11201912228WA (pt) |
TW (1) | TW201908342A (pt) |
WO (1) | WO2019016247A2 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211980T1 (hr) | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
HUE061841T2 (hu) | 2018-07-13 | 2023-08-28 | Alector Llc | Anti-sortilin antitestek és felhasználásuk módszerei |
WO2020160560A2 (en) * | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
WO2023247754A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
ES2228467T3 (es) | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso. |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
ATE545429T1 (de) | 2002-12-20 | 2012-03-15 | Lundbeck & Co As H | Modulation der neurotrophinaktivität;screeningsverfahren |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
LT3225251T (lt) | 2006-12-21 | 2020-04-10 | H. Lundbeck A/S | Proneurotrofinų veiklos moduliavimas |
JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
CA2712276A1 (en) * | 2008-01-16 | 2009-07-23 | Neurodyn, Inc. | Treating neurodegenerative diseases with progranulin (pgrn) |
US8377701B2 (en) | 2008-04-27 | 2013-02-19 | H. Lundbeck A/S | Specific ligands to sortilin |
EP2293667A4 (en) * | 2008-05-27 | 2012-07-18 | Kyowa Hakko Kirin Co Ltd | INTERLEUKIN 10 (IL-10R) RECEPTOR ANTIBODIES AND METHODS OF USE |
US20120039865A1 (en) | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
CN102439041B (zh) | 2008-12-19 | 2016-05-04 | H.隆德贝克有限公司 | 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节 |
WO2014071131A1 (en) | 2012-11-02 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
US10149836B2 (en) * | 2014-03-21 | 2018-12-11 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
JP6719384B2 (ja) * | 2014-03-27 | 2020-07-15 | ダイアックス コーポレーション | 糖尿病黄斑浮腫の治療のための組成物および方法 |
HRP20211980T1 (hr) * | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JP2020513009A (ja) * | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Pd−1、tim−3、およびlag−3を標的とする併用治療 |
HUE061841T2 (hu) * | 2018-07-13 | 2023-08-28 | Alector Llc | Anti-sortilin antitestek és felhasználásuk módszerei |
CN113151432A (zh) * | 2020-04-14 | 2021-07-23 | 郁金泰 | 神经退行性疾病检测和治疗的新靶标 |
-
2018
- 2018-07-17 US US16/037,790 patent/US10894833B2/en active Active
- 2018-07-18 CA CA3069391A patent/CA3069391A1/en active Pending
- 2018-07-18 KR KR1020207001250A patent/KR20200031610A/ko not_active Application Discontinuation
- 2018-07-18 EP EP18750343.8A patent/EP3655438A2/en active Pending
- 2018-07-18 IL IL271728A patent/IL271728B2/en unknown
- 2018-07-18 BR BR112019005428A patent/BR112019005428A2/pt not_active IP Right Cessation
- 2018-07-18 SG SG11201912228WA patent/SG11201912228WA/en unknown
- 2018-07-18 PE PE2020000100A patent/PE20210467A1/es unknown
- 2018-07-18 JO JOP/2020/0007A patent/JOP20200007A1/ar unknown
- 2018-07-18 EA EA201992688A patent/EA201992688A1/ru unknown
- 2018-07-18 JP JP2020502415A patent/JP2020527152A/ja active Pending
- 2018-07-18 CR CR20200027A patent/CR20200027A/es unknown
- 2018-07-18 CN CN201880047918.8A patent/CN110945029A/zh active Pending
- 2018-07-18 MA MA049633A patent/MA49633A/fr unknown
- 2018-07-18 AU AU2018303175A patent/AU2018303175A1/en active Pending
- 2018-07-18 WO PCT/EP2018/069460 patent/WO2019016247A2/en unknown
- 2018-07-18 RU RU2019140933A patent/RU2019140933A/ru unknown
- 2018-07-19 TW TW107124976A patent/TW201908342A/zh unknown
- 2018-07-20 AR ARP180102043 patent/AR112563A1/es unknown
-
2019
- 2019-12-13 CO CONC2019/0014090A patent/CO2019014090A2/es unknown
- 2019-12-18 PH PH12019502869A patent/PH12019502869A1/en unknown
-
2020
- 2020-01-09 CL CL2020000070A patent/CL2020000070A1/es unknown
- 2020-01-09 DO DO2020000006A patent/DOP2020000006A/es unknown
- 2020-01-16 EC ECSENADI20202935A patent/ECSP20002935A/es unknown
- 2020-01-17 NI NI202000005A patent/NI202000005A/es unknown
- 2020-12-11 US US17/118,934 patent/US20210292414A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2020000070A1 (es) | 2020-06-12 |
JOP20200007A1 (ar) | 2020-01-15 |
JP2020527152A (ja) | 2020-09-03 |
RU2019140933A (ru) | 2021-08-20 |
EP3655438A2 (en) | 2020-05-27 |
ECSP20002935A (es) | 2020-02-28 |
AR112563A1 (es) | 2019-11-13 |
EA201992688A1 (ru) | 2020-05-20 |
IL271728A (en) | 2020-02-27 |
CN110945029A (zh) | 2020-03-31 |
CA3069391A1 (en) | 2019-01-24 |
US20190023788A1 (en) | 2019-01-24 |
MA49633A (fr) | 2020-05-27 |
SG11201912228WA (en) | 2020-01-30 |
CO2019014090A2 (es) | 2020-01-17 |
DOP2020000006A (es) | 2020-07-15 |
IL271728B2 (en) | 2024-05-01 |
WO2019016247A3 (en) | 2019-06-20 |
IL271728B1 (en) | 2024-01-01 |
KR20200031610A (ko) | 2020-03-24 |
NI202000005A (es) | 2020-05-20 |
CR20200027A (es) | 2020-04-17 |
AU2018303175A1 (en) | 2020-01-16 |
US10894833B2 (en) | 2021-01-19 |
RU2019140933A3 (pt) | 2021-10-28 |
WO2019016247A2 (en) | 2019-01-24 |
TW201908342A (zh) | 2019-03-01 |
PE20210467A1 (es) | 2021-03-08 |
PH12019502869A1 (en) | 2020-09-28 |
US20210292414A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019005428A2 (pt) | agentes, usos e métodos de tratamento | |
MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
PH12016501307B1 (en) | Compounds | |
MA53937B1 (fr) | Compositions comprenant des souches bactériennes | |
UY37808A (es) | Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 | |
EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
TN2018000322A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
EA201791590A1 (ru) | Антитела к tau и их применение | |
EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
CO2017012988A2 (es) | Agentes, usos y métodos para el tratamiento | |
EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
UY37580A (es) | Compuestos novedosos que inhiben la actividad de cinasa lrrk2 | |
MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
PH12019501006A1 (en) | Synergistic dietary supplement compositions for improving brain health | |
BR112021014566A2 (pt) | Moduladores de gpr35 | |
EA201890234A1 (ru) | Слитые молекулы | |
EA201991753A1 (ru) | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков | |
MX2021001287A (es) | Métodos para tratar trastornos neurodegenerativos. | |
MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
MX2022001037A (es) | Cuptsm para el tratamiento de trastornos neurodegenerativos. | |
EA201992305A1 (ru) | Композиции и способы для лечения синуклеопатий | |
CL2017003359A1 (es) | Uso de extractos de hojas ugni molinae silvestre en el tratamiento de las enfermedades asociadas a mal plegamiento proteico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2731 DE 09-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |